Thank you, Madam Chair.
Thank you to all the witnesses for your testimony.
My first question is for BioCanRx.
Clinical trials are often the first pathway for patients to access innovative therapies. In your view, how can modernizing Canada's clinical trials framework improve patients' access while also strengthening our domestic life sciences ecosystem?